Belimumab and voclosporin have unique mechanisms of action, impacting their efficacy and safety profiles in lupus nephritis treatment. Payers consider clinical outcomes, cost, and value when ...

Belimumab added to standard of care induction therapy improved control of disease activity and led to a reduction in glucocorticoid dosages in real-world patients with proliferative lupus nephritis.

Belimumab was recently shown to reduce disease activity in patients with systemic lupus erythematosus. This observation raises important questions about where belimumab might best fit into the ...

While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a serious complication of systemic lupus ...

Clinical stage biopharma Kezar Life Sciences is discontinuing its lupus nephritis (LN) clinical programme following the death ...

Belimumab demonstrates notable efficacy for enhancing treatment outcomes among adults with active systemic lupus erythematosus when added to standard therapy. Belimumab demonstrates notable efficacy ...

EXTON, PA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

particularly glucocorticoids Using antimalarials and immunosuppressives both to control disease in the long term and avoid 'spare' glucocorticoids Belimumab Minor arthritis, mild pleurisy NSAIDs ...

Benlysta (belimumab) is a prescription drug that’s used to treat lupus and a complication of lupus. Benlysta’s cost may depend on factors such as your dosage, whether you have health insurance ...